WO2002002143A3 - Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents - Google Patents

Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents Download PDF

Info

Publication number
WO2002002143A3
WO2002002143A3 PCT/US2001/020958 US0120958W WO0202143A3 WO 2002002143 A3 WO2002002143 A3 WO 2002002143A3 US 0120958 W US0120958 W US 0120958W WO 0202143 A3 WO0202143 A3 WO 0202143A3
Authority
WO
WIPO (PCT)
Prior art keywords
enhancement
antibody
fusion protein
immune responses
mediated immune
Prior art date
Application number
PCT/US2001/020958
Other languages
French (fr)
Other versions
WO2002002143A2 (en
Inventor
Stephen D Gillies
Yan Lan
Sylvia A Holden
Original Assignee
Lexigen Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0112111-1A priority Critical patent/BR0112111A/en
Priority to AU2001271729A priority patent/AU2001271729B2/en
Priority to EP01950766A priority patent/EP1294401B1/en
Priority to AU7172901A priority patent/AU7172901A/en
Priority to DK01950766T priority patent/DK1294401T3/en
Priority to SK98-2003A priority patent/SK982003A3/en
Priority to JP2002506764A priority patent/JP5390055B2/en
Priority to MXPA02012734A priority patent/MXPA02012734A/en
Application filed by Lexigen Pharm Corp filed Critical Lexigen Pharm Corp
Priority to DE60129695T priority patent/DE60129695T2/en
Priority to HU0300868A priority patent/HUP0300868A3/en
Priority to CA2412845A priority patent/CA2412845C/en
Publication of WO2002002143A2 publication Critical patent/WO2002002143A2/en
Publication of WO2002002143A3 publication Critical patent/WO2002002143A3/en
Priority to NO20026245A priority patent/NO20026245L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Disclosed are methods and compositions for treating tumors. Disclosed methods and compositions enhance the uptake of immunocytokines into tumors, and are based on a combination of an immunocytokine with an immunocytokine uptake enhancing agent. Disclosed methods and compositions are particularly useful for reducing tumor size and metastasis in a mammal.
PCT/US2001/020958 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents WO2002002143A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP2002506764A JP5390055B2 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein-mediated immune response by combined therapy with immune cytokine uptake enhancer
EP01950766A EP1294401B1 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU7172901A AU7172901A (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DK01950766T DK1294401T3 (en) 2000-06-29 2001-06-29 Improvement of antibody / cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake preparations
SK98-2003A SK982003A3 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
BR0112111-1A BR0112111A (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
MXPA02012734A MXPA02012734A (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents.
AU2001271729A AU2001271729B2 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
DE60129695T DE60129695T2 (en) 2000-06-29 2001-06-29 INCREASING IMMUNE RESPONSES MEDIATED BY ANTIBODY CYTOKIN FUSION PROTEINS BY COMBINED TREATMENT WITH MEDICAMENTS FOR INCREASING IMMUNOCYTIC INJECTION
HU0300868A HUP0300868A3 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
CA2412845A CA2412845C (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
NO20026245A NO20026245L (en) 2000-06-29 2002-12-27 Enhancement of antibody cytokine infusion protein mediated immune responses by combination therapy with immunocytokine uptake enhancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21503800P 2000-06-29 2000-06-29
US60/215,038 2000-06-29

Publications (2)

Publication Number Publication Date
WO2002002143A2 WO2002002143A2 (en) 2002-01-10
WO2002002143A3 true WO2002002143A3 (en) 2002-07-18

Family

ID=22801380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020958 WO2002002143A2 (en) 2000-06-29 2001-06-29 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents

Country Status (22)

Country Link
US (2) US7517526B2 (en)
EP (1) EP1294401B1 (en)
JP (1) JP5390055B2 (en)
KR (1) KR20030064275A (en)
CN (1) CN1270775C (en)
AT (1) ATE368475T1 (en)
AU (2) AU2001271729B2 (en)
BR (1) BR0112111A (en)
CA (1) CA2412845C (en)
CZ (1) CZ2003214A3 (en)
DE (1) DE60129695T2 (en)
DK (1) DK1294401T3 (en)
ES (1) ES2288967T3 (en)
HU (1) HUP0300868A3 (en)
MX (1) MXPA02012734A (en)
NO (1) NO20026245L (en)
PL (1) PL358582A1 (en)
PT (1) PT1294401E (en)
RU (1) RU2272644C2 (en)
SK (1) SK982003A3 (en)
WO (1) WO2002002143A2 (en)
ZA (1) ZA200300759B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
EP1071468B1 (en) * 1998-04-15 2006-06-14 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
EP1187852B1 (en) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE316982T1 (en) * 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DE60122286T2 (en) * 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
BR0112111A (en) * 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
CA2440221C (en) * 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (en) * 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
EP1699821B1 (en) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
WO2005066348A2 (en) * 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR20070085886A (en) * 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
DE602006021335D1 (en) * 2005-10-21 2011-05-26 Hoffmann La Roche METHOD FOR THE RECOMBINANT EXPRESSION OF A POLYEPIDE
JP2009519024A (en) * 2005-12-15 2009-05-14 マイクロメット アクツィエン ゲゼルシャフト Domain-grafted antibody
JP5175214B2 (en) * 2005-12-30 2013-04-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Interleukin-12P40 variant with improved stability
BRPI0620795A2 (en) 2005-12-30 2011-11-22 Merck Patent Ges Mit Beschronkter Haftung anti-cd19 antibodies reduced immunogenicity
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
MX2009013752A (en) * 2007-06-28 2010-02-01 Philogen Spa Immunocytokines for cancer treatment in combination with chemotherapeutic agents.
CL2008002092A1 (en) * 2007-07-20 2009-05-29 Hoffmann La Roche Conjugate containing two or more antifusogenic peptides and an anti-cd-4 antibody; Method of production; pharmaceutical composition comprising it; antifusogenic polypeptides and use of the conjugate to treat viral infections.
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AU2009306711A1 (en) * 2008-10-21 2010-04-29 Merck Patent Gmbh Cancer treatments with radiation and immunocytokines
KR20120053042A (en) * 2009-08-17 2012-05-24 로슈 글리카트 아게 Targeted immunoconjugates
US20120244145A1 (en) * 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB201419184D0 (en) 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AU2018297248A1 (en) * 2017-07-03 2020-02-20 Torque Therapeutics, Inc. Fusion molecules targeting immune regulatory cells and uses thereof
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN113195523A (en) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12 heterodimer Fc fusion proteins
WO2020236655A1 (en) 2019-05-17 2020-11-26 Xencor, Inc. Il-7-fc-fusi0n proteins
US11851466B2 (en) 2019-10-03 2023-12-26 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
CA3162406A1 (en) 2020-01-10 2021-07-15 Vijaya Raghavan PATTABIRAMAN Modified il-2 polypeptides and uses thereof
BR112022020440A2 (en) * 2020-04-10 2022-12-27 Cytomx Therapeutics Inc ACTIVATIVE CYTOKINE CONSTRUCTS AND RELATED COMPOSITIONS AND METHODS
TW202304958A (en) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 Masked activatable cytokine constructs and related compositions and methods
KR20240041379A (en) * 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Checkpoint inhibitors conjugated to IL-2 and uses thereof
WO2023281481A1 (en) * 2021-07-09 2023-01-12 Bright Peak Therapeutics Antibody conjugates and manufacture thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256714A2 (en) * 1986-08-01 1988-02-24 Cetus Oncology Corporation Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
DE2952486A1 (en) * 1978-12-26 1980-07-17 Canon Kk ELECTROPHOTOGRAPHIC METHOD AND DEVICE FOR IMPLEMENTING IT
US4469797A (en) 1982-09-23 1984-09-04 Miles Laboratories, Inc. Digoxigenin immunogens, antibodies, labeled conjugates, and related derivatives
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (en) 1983-12-13 1985-07-11 원본미기재 Method for preparing erythropoietin
US5082658A (en) 1984-01-16 1992-01-21 Genentech, Inc. Gamma interferon-interleukin-2 synergism
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5679543A (en) 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5359035A (en) 1985-12-21 1994-10-25 Hoechst Aktiengesellschaft Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK173067B1 (en) 1986-06-27 1999-12-13 Univ Washington Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5508031A (en) 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
US5019368A (en) 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JP3040121B2 (en) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド Methods of treating tumor cells by inhibiting growth factor receptor function
US5120525A (en) 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6750329B1 (en) 1989-05-05 2004-06-15 Research Development Foundation Antibody delivery system for biological response modifiers
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE123065T1 (en) 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd PROTEINS AND THEIR PRODUCTION.
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
US20020037558A1 (en) * 1991-10-23 2002-03-28 Kin-Ming Lo E.coli produced immunoglobulin constructs
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
PT633929E (en) 1992-04-01 2004-07-30 Merix Bioscience Inc METHOD FOR PROLIFERATION (IN VITRO) OF DENTIFICAL CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENES
EP0615451B1 (en) 1992-05-26 2005-12-07 Immunex Corporation Novel cytokine that binds cd30
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
DE69332485T2 (en) 1992-08-11 2003-11-13 Harvard College Immunomodulatory peptides
DE4228839A1 (en) 1992-08-29 1994-03-03 Behringwerke Ag Methods for the detection and determination of mediators
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
CA2147499C (en) 1992-11-05 2010-10-19 Ron S. Israeli Prostate-specific membrane antigen
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
HUT73876A (en) 1993-04-29 1996-10-28 Abbott Lab Erythropoietin analog compositions and methods
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
JP3880064B2 (en) 1994-04-26 2007-02-14 ザ チルドレンズ メディカル センター コーポレイション Angiostatin and its use in inhibiting angiogenesis
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CU22615A1 (en) 1994-06-30 2000-02-10 Centro Inmunologia Molecular PROCEDURE FOR OBTAINING LESS IMMUNOGENIC MONOCLONAL ANTIBODIES. MONOCLONAL ANTIBODIES OBTAINED
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US6169070B1 (en) 1995-03-10 2001-01-02 Genentech, Inc. Mer receptor activation by gas6
US5719266A (en) 1995-03-17 1998-02-17 Eli Lilly And Company Anti-obesity proteins
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
KR19990028388A (en) 1995-06-30 1999-04-15 피터 지. 스트링거 How to Treat Diabetes
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5678543A (en) * 1995-11-16 1997-10-21 Portable Hyperbarics, Inc. Hyperbaric chamber
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
ATE218143T1 (en) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt USE OF BI- AND TRISPECIFIC ANTIBODIES TO INDUCE TUMOR IMMUNITY
EP0930892A1 (en) * 1996-10-16 1999-07-28 The Johns Hopkins University Cytokine enhanced immunotherapy for brain tumors
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
PT973550E (en) 1997-04-11 2003-01-31 Searle & Co ANTI-INTEGRINE ANTIBODIES ANTI-INTEGRINA AVB3
DK1037927T3 (en) * 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
CA2328081A1 (en) * 1998-04-17 1999-10-28 Lexigen Pharmaceuticals Corporation Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
AU3655899A (en) 1998-04-20 1999-11-08 Regents Of The University Of California, The Modified immunoglobulin molecules and methods for use thereof
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
CA2341029A1 (en) * 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
BR9913331A (en) * 1998-08-25 2001-05-15 Lexigen Pharm Corp Expression and export of angiogenesis inhibitors as immunofusins
US6646113B1 (en) 1998-09-17 2003-11-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding human survival of motor neuron-interacting protein 1 (SIP1) deletion mutants
US6335176B1 (en) 1998-10-16 2002-01-01 Pharmacopeia, Inc. Incorporation of phosphorylation sites
AU778939B2 (en) * 1999-01-07 2004-12-23 Emd Lexigen Research Center Corp. Expression and export of anti-obesity proteins as Fc fusion proteins
CN101173295A (en) 1999-05-06 2008-05-07 威克福雷大学 Compositions and methods for identifying antigens which elicit an immune response
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
EP1187852B1 (en) * 1999-05-19 2007-08-08 EMD Lexigen Research Center Corp. EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythopintin derivatives
CZ299516B6 (en) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
ATE316982T1 (en) * 1999-08-09 2006-02-15 Lexigen Pharm Corp MULTIPLE CYTOKINE ANTIBODIES COMPLEXES
DE60122286T2 (en) * 2000-02-11 2007-08-02 Merck Patent Gmbh INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
PT1719528E (en) * 2000-02-24 2012-01-06 Philogen Spa Compositions and methods for treatment of angiogenesis in pathological lesions
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001088117A2 (en) * 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
BR0112111A (en) * 2000-06-29 2003-05-06 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
US20040043457A1 (en) * 2001-01-18 2004-03-04 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
MXPA03007323A (en) * 2001-02-19 2003-12-12 Merck Patent Gmbh Artificial proteins with reduced immunogenicity.
ATE400030T1 (en) * 2001-02-19 2008-07-15 Merck Patent Gmbh METHOD FOR IDENTIFYING T CELL PITOPES AND ITS APPLICATION TO PRODUCING MOLECULES WITH REDUCED IMMUNOGENICITY
CA2440221C (en) * 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (en) * 2001-05-03 2011-04-28 Merck Patent Gmbh RECOMBINANT, TUMOR-SPECIFIC ANTIBODY AND ITS USE
WO2003048334A2 (en) * 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US6996009B2 (en) * 2002-06-21 2006-02-07 Micron Technology, Inc. NOR flash memory cell with high storage density
CA2510180C (en) * 2002-12-17 2012-09-11 Merck Patent Gesellschaft Mit Beschraenkter Haftung Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256714A2 (en) * 1986-08-01 1988-02-24 Cetus Oncology Corporation Combination therapy using anti-tumor monoclonal antibodies and/or immunotoxins with interleukin-2
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. LODE ET AL.: "Synergy between an antiangiogenic integrin alpha-v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 96, no. 4, 16 February 1999 (1999-02-16), Washington, DC, USA, pages 1591 - 1596, XP002134006 *
J. BASELGA ET AL.: "Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.", CANCER RESEARCH, vol. 58, no. 13, 1 July 1998 (1998-07-01), Philadelphia, PA, USA, pages 2825 - 2831, XP002195343 *
S. GILLIES ET AL.: "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases.", THE JOURNAL OF IMMUNOLOGY, vol. 160, no. 12, 15 June 1998 (1998-06-15), Baltimore, MD, USA, pages 6195 - 6203, XP002106576 *
S. HOLDEN ET AL.: "Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.", CLINICAL CANCER RESEARCH, vol. 7, no. 9, September 2001 (2001-09-01), Denville, NJ, USA, pages 2862 - 2869, XP001064696 *
S. HOLDEN ET AL.: "Augmentation of anti-tumor activity of KS-IL2 immunocytokine with chemotherapeutic agents.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 42, March 2001 (2001-03-01), USA, pages 683, XP002195344 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8907066B2 (en) 2009-04-22 2014-12-09 Merck Patent Gmbh Antibody fusion proteins with a modified FcRn binding site

Also Published As

Publication number Publication date
DE60129695T2 (en) 2008-06-05
DE60129695D1 (en) 2007-09-13
HUP0300868A3 (en) 2005-11-28
AU7172901A (en) 2002-01-14
ZA200300759B (en) 2004-04-28
CA2412845A1 (en) 2002-01-10
JP5390055B2 (en) 2014-01-15
MXPA02012734A (en) 2003-04-25
EP1294401A2 (en) 2003-03-26
JP2004501981A (en) 2004-01-22
CA2412845C (en) 2014-07-22
RU2272644C2 (en) 2006-03-27
PT1294401E (en) 2007-11-09
US20030049227A1 (en) 2003-03-13
WO2002002143A2 (en) 2002-01-10
EP1294401B1 (en) 2007-08-01
NO20026245L (en) 2003-02-26
DK1294401T3 (en) 2007-10-08
ES2288967T3 (en) 2008-02-01
CN1529619A (en) 2004-09-15
SK982003A3 (en) 2004-05-04
US20100297060A1 (en) 2010-11-25
ATE368475T1 (en) 2007-08-15
NO20026245D0 (en) 2002-12-27
AU2001271729B2 (en) 2007-01-04
US7517526B2 (en) 2009-04-14
BR0112111A (en) 2003-05-06
CN1270775C (en) 2006-08-23
HUP0300868A2 (en) 2003-07-28
KR20030064275A (en) 2003-07-31
CZ2003214A3 (en) 2003-08-13
PL358582A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
WO2002002143A3 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
WO2004034990A3 (en) Methods and compositions for use in treating cancer
ZA200005475B (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with anglogenesis inhibitor.
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
HK1046016A1 (en) Recombinant gelatin in vaccines
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
EP1572118A4 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
IL206604A (en) Transmembrane protein, 24p4c12, expressed in prostate cancer, immunogenic compositions comprising them and uses thereof
DE69230798D1 (en) RECOMBINANT IMMUNTOXINE
AU2002350623A1 (en) Targeted thrombosis by tissue factor polypeptides
AU2003223089A1 (en) Compositions and methods for treating cancer with an oncolytic viral agent
EP1364657A4 (en) Remedies for tumor in hematopoietic organs
BR9808958A (en) 1,2,4-benzotriazine oxide formulations
AU2001261360A1 (en) R-eliprodil for treating glaucoma
HU0202120D0 (en)
WO2002092012A3 (en) Compositions and methods for treating tumors bearing hmfg and cea antigens
WO2002024178A3 (en) Method for reducing toxicity of combined chemotherapies
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
WO2004017926A3 (en) Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.
ES1046984U (en) Multicuchillo (Machine-translation by Google Translate, not legally binding)
AU2002344086A1 (en) Foods comprising animal protein, method of softening the animal protein and softeners to be used in softening animal protein
IT249915Y1 (en) PANEL-SCRATCH COVERING IN LEAF AND WOOD FIBRATED LEATHER, FURNITURE AND OTHER.
IL160412A0 (en) Methods and pharmaceutical compositions for immune deception, particularly in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001950766

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012734

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2412845

Country of ref document: CA

Ref document number: 018119247

Country of ref document: CN

Ref document number: 1020027017778

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2003-214

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 982003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2003/00759

Country of ref document: ZA

Ref document number: 200300759

Country of ref document: ZA

ENP Entry into the national phase

Ref country code: RU

Ref document number: RU A

Ref document number: 2003100873

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001271729

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001950766

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020027017778

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2003-214

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1020027017778

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2001950766

Country of ref document: EP